相似文献
1
Barriers to use of pharmacotherapy for addiction disorders and how to overcome them.
Curr Psychiatry Rep. 2011 Oct;13(5):374-81. doi: 10.1007/s11920-011-0222-2.
2
Addiction pharmacotherapy 2000: new options, new challenges.
J Psychoactive Drugs. 2000 Oct-Dec;32(4):371-8. doi: 10.1080/02791072.2000.10400238.
3
Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers.
Psychol Serv. 2013 Nov;10(4):410-419. doi: 10.1037/a0030949. Epub 2013 Jan 28.
4
Behavioral health issue brief: pharmacotherapy treatment of alcoholism and drug addiction: overview and bibliography: year end report-2002.
Issue Brief Health Policy Track Serv. 2002 Dec 31:1-6.
5
A pharmaceutical industry perspective on the economics of treatments for alcohol and opioid use disorders.
Ann N Y Acad Sci. 2014 Oct;1327(1):112-30. doi: 10.1111/nyas.12538. Epub 2014 Sep 18.
6
Adoption and implementation of medications in addiction treatment programs.
J Addict Med. 2011 Mar;5(1):21-7. doi: 10.1097/ADM.0b013e3181d41ddb.
7
Analysis of barriers to adoption of buprenorphine maintenance therapy by family physicians.
Rural Remote Health. 2015;15:3019. Epub 2015 Feb 4.
8
Implementing buprenorphine in addiction treatment: payer and provider perspectives in Ohio.
Subst Abuse Treat Prev Policy. 2015 Mar 28;10:13. doi: 10.1186/s13011-015-0009-2.
9
Pharmacotherapeutic management of co-morbid alcohol and opioid use.
Expert Opin Pharmacother. 2020 May;21(7):823-839. doi: 10.1080/14656566.2020.1732349. Epub 2020 Feb 27.
10
Rational development of addiction pharmacotherapies: successes, failures, and prospects.
Cold Spring Harb Perspect Med. 2012 Jun;2(6):a012880. doi: 10.1101/cshperspect.a012880.
引用本文的文献
1
Implications of Genetic Attributions for Addiction in Adults Affected by Alcohol Use Disorder and Gambling Disorder.
Addict Res Theory. 2025;33(4):350-360. doi: 10.1080/16066359.2025.2468423. Epub 2025 Mar 3.
2
A Randomized Trial of Alcohol Telemedicine in Primary Care: Pharmacotherapy and Referral Outcomes.
J Gen Intern Med. 2025 Jul 9. doi: 10.1007/s11606-025-09708-y.
3
Primary Care Visit Frequency Is Associated With Diagnosis But Not Pharmacotherapy Prescribing for Patients With Alcohol Use Disorder : AUD Pharmacotherapy Prescribing in Primary Care.
J Behav Health Serv Res. 2025 Jul;52(3):542-552. doi: 10.1007/s11414-025-09942-6. Epub 2025 Mar 24.
4
Prevalence, patterns, and predictors of prescribing medications for opioid use disorder (MOUD) in the Inpatient setting.
Drug Alcohol Depend Rep. 2024 Nov 8;13:100292. doi: 10.1016/j.dadr.2024.100292. eCollection 2024 Dec.
5
A Survey of Medication Diffusion and Attitudes Among Indian Clinicians Toward Pharmacotherapies for Alcohol Use Disorder.
Indian J Psychol Med. 2024 Nov;46(6):544-551. doi: 10.1177/02537176241229197. Epub 2024 Feb 24.
6
Safety of naltrexone in patients with cirrhosis.
JHEP Rep. 2024 Apr 10;6(7):101095. doi: 10.1016/j.jhepr.2024.101095. eCollection 2024 Jul.
7
Internal Medicine Resident Addiction Training at the Veteran's Health Administration: A Qualitative Evaluation of Site Directors' Response to the 2022 ACGME Requirements.
J Gen Intern Med. 2024 Jun;39(8):1393-1399. doi: 10.1007/s11606-024-08639-4. Epub 2024 Feb 1.
8
Anti-hypertensive Medication Use Among People with and without Substance Use Disorders.
J Gen Intern Med. 2024 Feb;39(3):508-510. doi: 10.1007/s11606-023-08543-3. Epub 2023 Nov 27.
9
Co-occurring implementation strategies: The effects of academic detailing for opioid use disorder campaign on the advancing pharmacological treatments for opioid use disorder (ADaPT-OUD) study.
Implement Res Pract. 2023 Sep 14;4:26334895231199463. doi: 10.1177/26334895231199463. eCollection 2023 Jan-Dec.
10
Buprenorphine use and courses of care for opioid use disorder treatment within the Veterans Health Administration.
Drug Alcohol Depend. 2023 Jul 1;248:109902. doi: 10.1016/j.drugalcdep.2023.109902. Epub 2023 May 2.
本文引用的文献
1
Psychiatrist characteristics that influence use of buprenorphine medication-assisted treatment.
J Addict Med. 2010 Dec;4(4):197-203. doi: 10.1097/ADM.0b013e3181c816f3.
2
The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.
World J Biol Psychiatry. 2011 Apr;12(3):160-87. doi: 10.3109/15622975.2011.561872.
3
Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.
Psychol Addict Behav. 2011 Jun;25(2):215-24. doi: 10.1037/a0022776.
4
Buprenorphine: new treatment of opioid addiction in primary care.
Can Fam Physician. 2011 Mar;57(3):281-9.
5
Community-based addiction treatment staff attitudes about the usefulness of evidence-based addiction treatment and CBO organizational linkages to research institutions.
Eval Program Plann. 2011 Nov;34(4):356-65. doi: 10.1016/j.evalprogplan.2011.02.002. Epub 2011 Mar 10.
6
Counselor attitudes toward the use of naltrexone in substance abuse treatment: a multi-level modeling approach.
Addict Behav. 2011 Jun;36(6):576-583. doi: 10.1016/j.addbeh.2011.01.030. Epub 2011 Jan 28.
7
Using medication-assisted treatment for substance use disorders: evidence of barriers and facilitators of implementation.
Addict Behav. 2011 Jun;36(6):584-589. doi: 10.1016/j.addbeh.2011.01.032. Epub 2011 Jan 27.
8
Adoption and implementation of medications in addiction treatment programs.
J Addict Med. 2011 Mar;5(1):21-7. doi: 10.1097/ADM.0b013e3181d41ddb.
9
Policy implications of integrating buprenorphine/naloxone treatment and HIV care.
J Acquir Immune Defic Syndr. 2011 Mar 1;56 Suppl 1:S98-S104. doi: 10.1097/QAI.0b013e31820a9a97.
10
Integrating addiction medicine into graduate medical education in primary care: the time has come.
Ann Intern Med. 2011 Jan 4;154(1):56-9. doi: 10.7326/0003-4819-154-1-201101040-00008.
Zotero 插件